We hereby consent to the use in the prospectus constituting Post-Effective Amendment No. 1 to Form F-1 on Form F-3 (the “F-3”) filed with the United States Securities and Exchange Commission of (i) our report dated
February 20, 2021, on the consolidated financial statements of Titan Medical Inc. (the “Company”) relating to the years ended December 31, 2020 and 2019; (ii) our report dated March 30, 2020, on the financial statements of the Company relating to
the years ended December 31, 2019 and 2018, which includes an explanatory paragraph regarding going concern uncertainty; and (iii) our report dated March 30, 2020, on the financial statements of the Company relating to the years ended December 31,
2018 and 2017, which includes an explanatory paragraph regarding going concern uncertainty.